跳至主要内容
临床试验/NCT05618587
NCT05618587已完成2 期

Effect of Low-dose Lithium Therapy on Long COVID Symptoms: a Randomized Controlled Trial.

State University of New York at Buffalo1 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2022年11月28日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
52
试验地点
1
主要终点
Fatigue Severity Scale

研究概览

简要总结

This study will assess low-dose lithium's effects on several different symptoms experienced by long COVID patients.

详细描述

In this double-blind, placebo-controlled study, 50 patients with long COVID will be randomly assigned to either low-dose oral lithium or placebo therapy for three weeks. After the double-blind study phase, all patients will be provided with lithium therapy for two additional weeks. Study visits will occur at baseline and after the three-week double-blind study phase.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Lithium

Experimental

Lithium 10mg po qd

干预措施: Lithium (Drug)

Placebo

Placebo Comparator

Placebo identically matching the lithium pills

干预措施: Placebo (Drug)

结局指标

主要结局

Fatigue Severity Scale

时间窗: Change from baseline to day 21

7-item questionnaire assessing fatigue severity. Score range 1-49 with higher values signifying worse outcome

Brain Fog Severity Scale

时间窗: Change from baseline to day 21

7-item questionnaire assessing brain fog severity. Score range 1-49 with higher values signifying worse outcome

次要结局

  • Patient Global Impression of Change (PGIC)(Day 21)
  • Well-Being Scale(Change from baseline to day 21)
  • Short Form-12 Health Survey (1-week Modification)(Change from baseline to day 21)
  • Desire to Continue Therapy(Day 21)
  • Generalized Anxiety Disorder-2 Scale(Change from baseline to day 21)
  • Headache and Body Pain Bother Scale(Change from baseline to day 21)
  • Insomnia Severity Index(Change from baseline to day 21)
  • Sense of Smell and Taste Change Scale(Day 21)
  • Digit Symbol Substitution Test(Change from baseline to day 21)
  • Delayed Recall Test(Change from baseline to day 21)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Thomas Guttuso

Professor of Neurology

State University of New York at Buffalo

研究点 (1)

Loading locations...

相似试验